Citi analyst Geoff Meacham views Moderna’s (MRNA) $2.3B settlement with Arbutus as not the best-case scenario of an outright win but better than feared. The news is likely to come as a relief to many investors, the analyst tells investors in a research note. Citi thinks the settlement removes an overhang for the stock and keeps a Neutral rating on Moderna with a $41 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna: Legal Overhang Eased but Valuation, Cash Headwinds and Respiratory Concentration Justify Neutral Stance
- Closing Bell Movers: GitLab down 9% on earnings, AI threat
- Moderna: Litigation Relief Supports Oncology Pipeline, But Legal Overhang Keeps Risk‑Reward Balanced at Hold
- Why Is SPY ETF Down Today, 3/3/2026?
- Moderna resolves litigation with Arbutus Biopharma, to pay $900M